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Abstract
Background: Human hemangiosarcoma (HSA) tends to have a poor prognosis; its tumorigenesis has not been elucidated, as
there is a dearth of HSA clinical specimens and no experimental model for HSA. However, the incidence of spontaneous HSA
is relatively high in canines; therefore, canine HSA has been useful in the study of human HSA. Recently, the production of
angiogenic growth factors and their receptors in human and canine HSA has been reported. Moreover, the growth-factor
environment of HSA is very similar to that of pathophysiological angiogenesis, which some homeobox genes regulate in the
transcription of angiogenic molecules. In the present study, we established 6 xenograft canine HSA tumors and detected the
expression of growth factors, their receptors, and angiogenic homeobox genes.
Methods: Six primary canine HSAs were xenografted to nude mice subcutaneously and serially transplanted. Subsequently, the
expressions of vascular endothelial growth factor (VEGF)-A, basic fibroblast growth factors (bFGF), flt-1 and flk-1 (receptors of
VEGF-A), FGFR-1, and angiogenic homeobox genes HoxA9, HoxB3, HoxB7, HoxD3, Pbx1, and Meis1 were investigated in
original and xenograft tumors by histopathology, immunostaining, and reverse transcription polymerase chain reaction (RT-
PCR), using canine-specific primer sets.
Results: Histopathologically, xenograft tumors comprised a proliferation of neoplastic cells that were varied in shape, from
spindle-shaped and polygonal to ovoid; some vascular-like structures and vascular clefts of channels were observed, similar to
those in the original tumors. The expression of endothelial markers (CD31 and vWF) was detected in xenograft tumors by
immunohistochemistry and RT-PCR. Moreover, the expression of VEGF-A, bFGF, flt-1, flk-1, FGFR-1, HoxA9, HoxB3, HoxB7,
HoxD3, Pbx1, and Meis1 was detected in xenograft tumors. Interestingly, expressions of bFGF tended to be higher in 3 of the
xenograft HSA tumors than in the other tumors.
Conclusion: We established 6 xenograft canine HSA tumors in nude mice and found that the expressions of angiogenic growth
factors and their receptors in xenograft HSAs were similar to those in spontaneous HSA. Furthermore, we detected the
expression of angiogenic homeobox genes; therefore, xenograft models may be useful in analyzing malignant growth in HSA.
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Background
Hemangiosarcoma (HSA) is a malignant neoplasm that
originates from vascular endothelial cells (ECs). In gen-
eral, high-grade, aggressive tumors tend to recur locally
and metastasize early, despite therapeutic modality [1-4].
However, the mechanisms of tumorigenesis in HSA have
been barely elucidated, since these tumors comprise only
approximately 2% of all cases of soft-tissue sarcoma in
humans. In contrast, spontaneous HSA occurs more fre-
quently in dogs than in any other species [5]; in fact, there
are more occasions to gain new insights into canine HSA
than into human HSA [6-8]. Knowledge obtained from
the study of canine HSA is useful in understanding human
HSA. In recent studies into canine and human HSA,
expressions of both vascular endothelial growth factor A
(VEGF-A) and their receptors, especially flk-1, were evi-
dent, and the presence of an autocrine or paracrine mech-
anism underpinning the growth factors might be
associated with the malignant proliferation of canine HSA
[9,10]. Considering the similarities shared by human and
canine HSAs, a canine HSA model may be useful in the
study of human HSA.
Homeobox genes encode homeodomain-containing pro-
teins, which regulate morphogenesis and cell differentia-
tion as a transcription factor in embryonic development.
Homeobox genes are highly conserved among various
species, and thus they may serve a function similar to that
of the corresponding genes in various animals, from sim-
ple organisms to vertebrates, including humans [11,12].
Some homeobox genes tightly regulate the behavior of
ECs during VEGF or bFGF-induced angiogenesis [13-18].
Regarding growth factor environments, HSA may have a
growth mechanism similar to that of pathophysiological
angiogenesis, and angiogenesis-associated homeobox
genes may play a function in HSA. We hypothesized that
angiogenic homeobox genes are also associated with the
malignant behavior of HSA, which is rendered possible by
the proliferation and invasion of neoplastic ECs.
Several in vitro models have been established and used to
carry out biological and molecular characterization of
canine HSA [19,20]. On the other hand, experimental in
vivo study models are essential for dynamic analysis of
neoplasm. For instance, the pharmaceutical analysis of
anticancer drugs with a consideration of drug metabolism
is essential because the handling of clinical or fixed his-
topathological tumor samples is restricted. A transplanta-
ble neoplastic model is useful in the dynamic analysis of
neoplasm  in vivo; in human medical research, tumor
xenografts have been widely used and have greatly con-
tributed to advancements in the medical sciences [21-23].
In the present study, we attempted to transplant
xenografts of canine HSA tumors into athymic nude mice.
We were able to establish 6 xenograft tumors derived from
6 spontaneous canine HSAs and subsequently analyze the
expression of VEGF-A, basic fibroblast growth factor
(bFGF), their receptors, and angiogenesis-associated
homeobox genes in established canine HSA xenograft
tumors.
Methods
Sources of Canine Hemangiosarcoma Tumors
A total of 6 xenograft tumors (Si, Re, Ud, Sy, Sa, and Ju)
were established from 6 spontaneous canine HSAs that
were collected from the Veterinary Teaching Hospital of
Gifu University or from private animal hospitals. Re was
obtained during necropsy of a dog with systemic metasta-
sized HSA and the remaining 5 samples were obtained by
surgical excision. Information of dogs with original
tumors is provided in Table 1.
After surgical removal or necropsy, these tumors were
immediately prepared for histopathology and transplan-
tation. For histopathological examination, these tumors
were fixed in 10% neutral buffered formalin and embed-
ded in paraffin, in a routine manner. Tissue sections from
the original tumors were stained with hematoxylin and
eosin (HE), as is customary. To transplant tumor to mice,
tumor tissues were cut into 1-mm3 cubes under sterile
conditions.
Nude Mice and Transplantations of Canine HSA Tissue to 
Nude Mice
Three-week-old male KSN Slc mice (Japan SLC, Inc.,
Hamamatsu, Japan) were anesthetized with pentobarbital
and subcutaneously xenografted with tumor tissue flaps
Table 1: An information of original tumors
Xenografted tumor Breed Sex Age Metastasis Transplantation tissue
Si Mix SF 13 y Spleen
Re Golden retriever CM 10 y Systemic metastasis Right auricle
Ud Papillon F 11 y Spleen
Sy Golden retriever M 7 y Left elbow
Sa Husky CM 11 y Liver and inguinal subcutis Spleen
Ju Labrador retriever SF 10 y Liver
CM: castrated male, SF: spayed female.BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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in the right or left dorsal area of the trunk. The skin was
cleaned using 70% ethanol and a small skin incision was
made. The tumor tissue flap was then introduced into the
subcutaneous pocket with a transplantation needle (ϕ 2.0
mm). After injection, the tumor sizes were measured once
a week. Putative tumor volume (V) was calculated as
(width)2  × length/2 mm3. Tumor volumes were then
expressed as fractional tumor volumes (V/V0), where V0 is
the initial volume of the tumor immediately before treat-
ment (day 0). When the tumors had increased to approx-
imately 10 mm in diameter, tumors growing in nude mice
were serially transplanted from mouse to mouse. The
mice were scarified, and the tumor was immediately
removed. Subsequently, several pieces of the xenografted
tumor tissues were stored in a freeze-stock solution (Cell
Banker; Nippon Zenyaku Kogyo Co., Fukushima, Japan)
in a deep freezer at -80°C to confirm the tumorigenicity of
frozen xenografted tumor tissues. All the excised tumors
were treated the same as the spontaneous tumors for his-
topathological analyses. Snap-frozen samples were also
collected for reverse transcriptase polymerase chain reac-
tion (RT-PCR) and stored at -80°C until use. The experi-
ments were performed according to the guidelines for the
care and use of laboratory animals approved by the Ani-
mal Care and Use Committee of Gifu University.
Immunohistochemical Staining of Original or Xenograft 
Tumors
Immunohistochemical staining was performed for CD31
(anti-human CD31 mouse monoclonal antibody, predi-
luted; Dako Cytomation, Glostrup, Denmark), von Wille-
brand factor (anti-human von Willebrand factor rabbit
monoclonal antibody [vWF], prediluted; Dako Cytoma-
tion), Ki-67 antigen (anti-human Ki-67 antigen mouse
monoclonal antibody, clone MIB-1, 1:25; Dako Cytoma-
tion), VEGF-A (anti-human VEGF [C-1] mouse mono-
clonal antibody, 1:50; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), flt-1 (anti-human flt-1 [C-17] rabbit pol-
yclonal antibody, 1:200; Santa Cruz Biotechnology), flk-1
(anti-mouse flk-1 [A-3] mouse monoclonal antibody,
1:200; Santa Cruz Biotechnology), bFGF (anti-human
FGF-2 [147] rabbit polyclonal antibody, 1:200; Santa
Cruz Biotechnology), HoxA9 (anti-human HoxA9 [A-20]
goat polyclonal antibody, 1:200; Santa Cruz Biotechnol-
ogy), HoxB3 (anti-human HoxB3 [C-20] goat polyclonal
antibody, 1:100; Santa Cruz Biotechnology), HoxB7
(anti-human HoxB7 rabbit polyclonal antibody, 1:1,000;
CeMines, Golden, CO, USA), HoxD3 (anti-human
HoxD3 rabbit polyclonal antibody, 1:400; Aviva Systems
Biology, San Diego, CA, USA), Pbx1 (anti-human Pbx1
rabbit polyclonal antibody, 1:100; Novus Biologicals, Lit-
tleton, CO, USA), and Meis1 (anti-human Meis1 rabbit
polyclonal antibody, 1:200; Abcam, Tokyo, Japan) for all
the original tumor and xenograft samples that had been
transplanted more than 5 times consecutively and then
transplanted into frozen xenografted tumor tissues. These
antibodies have been reported to be able to react with
peptides of canine origin [10,24-27]. Antibodies to
HoxB7, Pbx1, and Meis1 are purified against a synthetic
peptide whose sequence is identical to the canine peptide
[28]. Although the antibodies to HoxA9, HoxB3, and
HoxD3 are purified against corresponding peptides of the
human protein regions, it is unclear whether or not these
sequences corresponded to protein sequences in canines.
To demonstrate the staining characteristics for those anti-
bodies in angiogenic status, canine granulation tissue was
immunohistochemically stained. HoxD3 was used at a
dilution attained by adding Can Get Signal.® immunos-
tain Solution A (Toyobo, Osaka, Japan). Ki-67 antigen,
VEGF-A, flt-1, flk-1, bFGF, HoxA9, HoxB3, HoxB7, Pbx1,
and Meis1 were diluted by adding 1% bovine albumin/
phosphate-buffered saline (PBS). In brief, 3-μm sections
were deparaffinized in Lemosol (Wako Pure Chemical
Industries, Osaka, Japan) and rehydrated in graded etha-
nol. For the antigen retrieval of vWF, flk-1, flt-1, HoxA9,
HoxB3, HoxB7, Pbx1, and Meis1, sections were immersed
in Target Retrieval Solution (Dako Cytomation) and
heated for 15 min at 121°C in an autoclave. For antigen
retrieval of Ki-67, sections were immersed in Target
Retrieval Solution and heated for 25 min at 121°C in an
autoclave. For demasking CD31, sections were digested
with 0.5% proteinase K (Takara, Ohtsu, Japan) in Tris-
HCl buffer (pH 7.0) for 5 min at 37°C. For demasking
VEGF-A and bFGF, sections were digested with 0.1%
trypsin (GIBCO Life Technologies, NY, USA) in Tris-HCl
buffer (pH 7.0) for 15 min at 37°C. Endogenous peroxi-
dase was blocked by incubation in 0.3% H2O2 in metha-
nol for 20 min at room temperature (RT). To prevent the
binding of nonspecific proteins to the primary antibody,
the sections were treated with Protein Block Serum-Free
(Dako Cytomation) for 30 min at RT. Sections were incu-
bated with the primary antibody overnight at 4°C; for the
negative control, PBS was used in place of the primary
antibody. The sections were then washed with PBS and
incubated with the appropriate secondary antibodies
(Histofine.® simple stain MAX PO; Nichirei, Tokyo, Japan)
at RT for 30 min. After washing thrice with PBS, binding
was detected using 3,3'-diaminobenzidinetetrahydrochlo-
ride (Liquid DAB + Substrate Chromogen System; Dako
Cytomation). Finally, the sections were washed in dis-
tilled water and counterstained with Mayer's hematoxylin.
The percentage of Ki-67-positive cells in each tumor tissue
was calculated as the number of reddish brown-positive
nuclei in a total of 1000 neoplastic cells (from 10 high-
power fields); this value is indicated as a Ki-67 positive
index (PI).
Detection of mRNA Expression by RT-PCR
Total RNA was extracted from 6 xenograft tumors using
TRIzol reagent (Gibco Life Technologies). In brief, a snap-
frozen sample was homogenized in 1 ml TRIzol by a pol-BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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ytron-type homogenizer and mixed with 0.2 ml chloro-
form before centrifugation. The aqueous phase was
collected for total RNA extraction, mixed with 2-propanol
to salt out, and washed with chilled 75% ethanol. Total
RNA was detected after treatment with amplification-
grade DNase I (Invitrogen, Carlsbad, CA, USA) followed
by RT-PCR assay with Qiagen One step RT-PCR Kit (Qia-
gen, Valencia, CA, USA), according to the manufacturer's
instructions. RT-PCR was carried out in a Thermal Cycler
Dice Gradient (Takara). Amplifications were performed
under the following conditions: reverse-transcription
reaction for 30 min at 50°C, an initial polymerase activa-
tion step for 15 min at 95°C, denaturation for 30 s at
95°C, annealing for 30 s, extension for 1 min at 72°C,
and a final extension for 10 min at 72°C. To confirm the
omission of genomic contamination, RT-PCR was carried
out for DNase I-treated total RNA with One Step Enzyme
Mix, which was deactivated for reverse transcription activ-
ity by heating at 95°C for 15 min.
The primer sequences, annealing temperatures, annealing
cycle number, product sizes used, and the accession
number for generating the primer sets are listed in Addi-
tional file 1. Each primer used in this study was generated
from canine-specific sequences, by accession number
(e.g., Genbank). The sequences that the primers recognize
in the sandwich splicing area and the predicted sizes dif-
fered among VEGF variants. The primers amplifying
HoxA9 mRNA distinguished between HoxA9 mRNA,
which contains the region encoding the homeodomain,
and the HoxA9 mRNA lacking this region. RNA integrity
was confirmed by the sufficient amplification of β-actin.
The specificity of all canine primer sets was definitive,
because there was no band in the RT-PCR for normal
mouse spleens. The products of the PCR amplifications
were electrophoresed in 2% agarose gel or 7.5% polyacry-
lamide gel for VEGF stained with ethidium bromide and
visualized under ultraviolet light.
Results
Tumor Xenografts
Of the 13 spontaneous canine HSA xenografts we
attempted to establish in nude mice, 6 were successful and
resulted in 6 growing canine HSA tumors. All these
tumors were serially transplanted from mouse to mouse at
least 5 times and had been maintained for over a year on
nude mice. All the tumors grew to large masses (approxi-
mately 500 mm3 each) in the subcutis of nude mice, at 3-
6 weeks after the pieces of the original tumors had been
inoculated (Figure 1). There were no significant changes
in the growth rate through passages in all xenograft
tumors (data not shown). All frozen samples from
xenograft tissues successfully formed tumors in nude
mice. With the exception of tumor formation, no clinical
abnormalities were observed in any of the transplanted
mice during their experimental term. Grossly, none of the
xenograft tumors adhered to underlying muscles or over-
lying skins, and the tumors were discretely formed. The
tumors were soft and had a dark reddish hue on the cut
surface. At necropsy, no metastatic lesions were observed
in any of the organs.
Histopathology
Histopathologically, all original tumors comprised prolif-
erations of neoplastic cells that were highly variable in
shape, ranging from spindle-shaped and polygonal to
ovoid (Figure 2A, C, E, G, I, and 2K). There were some vas-
cular-like structures and vascular clefts of channels that
contained erythrocytes, neutrophils, and lymphocytes.
Similarly, all xenograft tumors, including the tumors from
the frozen xenografts, comprised clusters of small sheets
of pleomorphic to plump spindle cells that frequently
formed slit-like spaces, many of which also contained
erythrocytes, neutrophils, and lymphocytes (Figure 2B, D,
F, H, J, and 2L). The nuclei of neoplastic cells comprising
the xenograft tumors sustained more severe anisokaryosis
than those in the original tumors. Necrotic foci were scat-
tered. Similar to original tumors, mitotic figures were fre-
quent in all xenograft tumors. The neoplastic cells
invaded into the subcutaneous adipose tissue in the
peripheral area of neoplastic proliferation. Compared to
Gross appearance of Ud xenograft tumors at 24 days after  transplantation, which was transplanted repeatedly 20 times Figure 1
Gross appearance of Ud xenograft tumors at 24 days 
after transplantation, which was transplanted repeat-
edly 20 times. The xenograft tumor was solid, dark red in 
color, and contained necrotic and blood-filled areas on the 
cut surface. Bar: 2.5 mm.BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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the original tumors, the xenograft tissues tended not to
form vascular-like clefts of channels.
Immunohistochemical Analysis
The presence of CD31 and vWF--both of which confirmed
the endothelial nature of the tumors--was detected by
immunohistochemical staining in all original tumors and
xenograft tumors including the tumors from frozen
xenografts (Figure 3A-D). CD31 was positive for the cyto-
plasmic borders of neoplastic cells and vWF was positive
for diffuse or patchy cytoplasm. The neoplastic cells were
also positive for MIB-1 (Figure 3E). The Ki-67 PIs of the
xenograft samples (mean PI, 55.7%; range, 47.2-70.7%)
were equal to or higher than those of the original tumors
(mean PI, 39.3%; range, 28.6-51.2%) in all tumors.
Immunohistochemical staining on all xenograft tumors,
including the tumors from frozen xenografts, and original
tumors were positive for antibodies against VEGF-A, flt-1,
flk-1, and bFGF (Figure 4). Most ECs in the proliferating
capillaries of canine granulation tissue were labeled by
primary antibodies for HoxA9, HoxB3, HoxB7, HoxD3,
Pbx1, and Meis1, and the proteins were expressed in both
the nucleus and the cytoplasm. HoxD3 (Figure 5A) and
Pbx1 (Figure 5C) had weaker expression in the nucleus
Histological features of original HSAs and xenograft HSA tumors Figure 2
Histological features of original HSAs and xenograft HSA tumors. Microscopic features of original HSAs and 
xenograft HSA tumors. Histologically, each of the original HSAs (A, C, E, G, I, and K present the original tumors of Si, Re, Ud, 
Sy, Sa, and Ju, respectively) showed vascular-like proliferation and formed solid sheets with various-sized clefts. The neoplastic 
cells that comprised original tumors had various shapes, ranging from spindle-shaped and polygonal to ovoid. Each of the 
xenograft tumors (B, D, F, H, J, and L present Si, Re, Ud, Sy, Sa, and Ju, respectively) were predominantly solid and contained 
poorly formed, irregular-shaped vascular spaces with erythrocytes, neutrophils, and lymphocytes. In all xenograft tumors, the 
neoplastic cells became more pleomorphic, elongated, and plump and the nuclei became larger and more clearly polygonal in 
shape. Hematoxylin and eosin (HE); bars: 50 μm.BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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than in the cytoplasm of these cells. In contrast, quiescent
ECs in mature vessels had strong nuclear expression of
HoxB3 and Meis1, but their expression in the cytoplasm
was weak or absent. HoxA9 and HoxB7 were positive only
in the nuclei of these cells, and HoxD3 (Figure 5B) and
Pbx1 (Figure 5D) were absent or weakly positive in quies-
cent ECs. HoxA9, HoxB3, Pbx1, and Meis1 were strongly
expressed within the nuclei and cytoplasm of neutrophils
and macrophages, but HoxB7 expression was restricted to
the nuclei of these cells. Moreover, HoxA9, HoxB3,
HoxB7, HoxD3, Pbx1, and Meis1 were positive in all the
original tumors and xenograft tumors, including the
tumors from frozen xenografts (Figure 5E-P). HoxA9,
HoxB3, HoxD3, Pbx1, and Meis1 were positive in the
nuclei and cytoplasm of neoplastic cells in all original
tumors and xenograft tumors. Cytoplasmic immunoreac-
tivity for HoxA9, HoxB3, Pbx1, and Meis1 was found to be
diffuse in all original and xenograft tumors, and cytoplas-
mic immunoreactivity for HoxD3 was also found to be
diffuse or localized in all original tumors and xenograft
tumors, particularly in the perinuclear area. HoxB7 was
strongly positive for the nuclei of neoplastic cells in all
original tumors and xenograft tumors.
Expression of CD31, vWF, VEGF-A, flt-1, flk-1, bFGF, FGFR-
1, EphB4, and Angiogenic Homeobox Genes
The results of RT-PCR are shown in Figure 6. In the ampli-
fication of VEGF-A mRNA by RT-PCR, 2 major bands
(177- and 249-bp bands corresponding to VEGF-A164 and
VEGF-A188  mRNA, respectively) were detected in all
xenograft tumors and normal canine spleen samples;
however, the 231-bp band corresponding to VEGF-A182
was not present. Amplification for CD31, vWF, flt-1, flk-1,
bFGF, FGFR-1, and EphB4 mRNA yielded single 211-,
221-, 156-, 187-, 234-, 162-, and 178-bp products, respec-
tively, in all xenograft tumors and normal spleen samples.
The expression of bFGF mRNA was more obvious in the
Si, Ud, and Sy xenograft tumors. In the amplification of
the HoxA9 mRNA by RT-PCR, 2 bands (314-bp and 141-
bp bands corresponding to HoxA9 mRNA containing the
region encoding the homeodomain and HoxA9 mRNA
lacking it, respectively) were detected in all xenograft
tumors and normal canine spleen samples. The 141-bp
band was less intense than the 314-bp band in all the
xenograft tumors and normal canine spleen samples.
Amplification for HoxB3, HoxB7, HoxD3, Pbx1, and
Meis1 mRNA yielded single 198-bp, 243-bp, 165-bp, 232-
bp, and 284-bp products, respectively, in all xenograft
tumors and normal spleen samples.
Discussion
In this study, 6 xenograft canine HSAs were established. As
compared to the original tumors, xenograft tissues tended
to form neither vascular-like clefts of channels nor higher
nuclear atypia of xenograft tumors; however, the his-
topathological structures of xenograft tumors were similar
to those in original canine HSA, and mRNA expressions
and immunoreactivities of vWF and CD31 were also
detected in the xenograft tumors. Thus, the xenograft
tumors in the present study maintained the canine
endothelial nature. In immunohistochemistry for Ki-67
Endothelial cell-specific markers and Ki-67 immunolabeled in  original HSAs and xenograft HSA tumors Figure 3
Endothelial cell-specific markers and Ki-67 immu-
nolabeled in original HSAs and xenograft HSA 
tumors. Immunolabeling of CD31, vWF, and Ki-67, in origi-
nal HSAs and xenograft HSA tumors. All original HSAs had 
membrane immunoreactivity for CD31 (A: the original 
tumor of Sa) and cytoplasmic immunoreactivity for vWF (C: 
the original tumor of Sa). Immunoreactivity for CD31 (B: Sa) 
and vWF (D: Sa) in all xenograft HSA tumors was detected in 
the same location as in the original tumors. In all xenograft 
HSA tumors, Ki-67 (E: Sy) nuclear immunoreactivity was 
observed in the nuclei of the tumor cells that were derived 
from canine HSA. Immunohistochemistry (IHC); bars: 50 μm.BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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antigen using antibody clone MIB-1, xenograft tumor cells
were clearly positive in the nucleus but negative in the sur-
rounding murine tissues such as the epidermal basal cells.
The MIB-1 antibody did not react with murine homolo-
gous antigen but reacted with canine homologous anti-
gen; thus, xenograft tumors were confirmed as being of
canine origin [29]. Some xenograft tumors indicated
higher Ki-67 PI values than those of original tumors. Thus,
given the atypia and the Ki-67 PI of the original and
xenograft tumors, it is suggested that more malignant
components may be selected by repeated xenotransplan-
tation.
In spontaneous canine HSAs, the mRNA of VEGF-A and
bFGF and their receptors were detected; however, they can
be immunohistochemically detected not only in neoplas-
tic cells but also in inflammatory cells [10]. Actually, the
results of RT-PCR in spontaneous canine HSA uncovered
the presence of both neoplastic cells and infiltrating
inflammatory cells [10]. Thus, contaminated inflamma-
tory cells could disrupt HSA analysis, especially the detec-
tion of gene expression; it is difficult to resolve this
problem when using solely clinical samples. We
attempted to establish xenograft models in the present
study, as they are powerful tools in resolving this prob-
lem. Because the expression of VEGF-A, flt-1, flk-1, bFGF,
and FGFR-1 mRNA was detected in xenograft tumors by
the canine-specific primers, amplified products originated
precisely from canine neoplastic ECs. These results suggest
that accurate gene expression could be detected in the
xenograft models established in the present study. In
addition, xenograft HSA tumors showed positive immu-
nolabeling for VEGF-A, bFGF, flt-1, and flk-1, similar to
the original tumors; thus, those xenograft models main-
tain a proliferative mechanism similar to that found in
spontaneous canine HSA.
There is increasing evidence that the dysregulation of
molecular pathways governing angiogenesis may be
important to HSA pathogenesis [30]. Yonemaru et al. sug-
gest that canine HSA might have an autocrine or a para-
crine mechanism via VEGF-A and/or bFGF receptor(s)
[10]. VEGF-A, a strong angiogenic factor, is expressed at
low levels in normal mammalian tissues; increased levels
of VEGF-A were observed during ischemia or hypoxia, and
in lesions characterized by angiogenesis. In a recent study
[31], VEGF-A120, VEGF-A164, and VEGF-A188 were detected
in normal canine tissues, and VEGF-A164, which corre-
Angiogenic growth factors and their receptors immunolabeled in original HSAs and xenograft HSA tumors Figure 4
Angiogenic growth factors and their receptors immunolabeled in original HSAs and xenograft HSA tumors. 
Representative immunohistochemical results of VEGF-A, flt-1, flk-1, and bFGF in original HSAs and xenograft HSA tumors. All 
original HSAs had cytoplasmic immunoreactivity for VEGF-A (A: the original tumor of Re), flt-1 (C: the original tumor of Ju), 
flk-1 (E: the original tumor of Ud), and bFGF (G: the original tumor of Si). Immunoreactivity for VEGF-A (B: Re), flt-1 (D: Ju), 
flk-1 (F: Ud), and bFGF (H: Si) in all xenograft HSA tumors was detected in the same location as in the original tumors. Immu-
nohistochemistry (IHC); bars: 50 μm.BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
Page 8 of 12
(page number not for citation purposes)
Angiogenesis-associated homeobox proteins immunolabeled in canine normal ECs, original HSAs, and xenograft HSA tumors Figure 5
Angiogenesis-associated homeobox proteins immunolabeled in canine normal ECs, original HSAs, and 
xenograft HSA tumors. Representative immunohistochemical results of HoxD3 and Pbx1 in active and quiescent ECs dur-
ing angiogenesis. In granulation tissue, although immunoreactivity for HoxD3 (A) and Pbx1 (C) was localized in the nuclei and 
cytoplasm of angiogenic ECs, it was weak for HoxD3 in the nuclei. Immunoreactivity for HoxD3 (B) was not detected in quies-
cent ECs but for Pbx1 (D), the immunoreactivity was localized in the nuclei and cytoplasm of quiescent ECs. Representative 
immunohistochemical results of HoxA9, HoxB3, HoxB7, HoxD3, Pbx1, and Meis1 in original HSAs and xenograft HSA tumors. 
In all original HSAs, immunoreactivity for HoxA9 (E: the original tumor of Ud), HoxB3 (G: the original tumor of Sy), HoxD3 
(K: the original tumor of Sa), Pbx1 (M: the original tumor of Ud), and Meis1 (O: the original tumor of Ud) was localized in the 
nuclei and cytoplasm of the neoplastic cells. HoxB7 (I: the original tumor of Sa) immunoreactivity was only localized in the 
nuclei of the neoplastic cells. Immunoreactivity for HoxA9 (F: Ud), HoxB3 (H: Sy), HoxB7 (J: Sa), HoxD3 (L: Sa), Pbx1 (N: Ud), 
and Meis1 (P: Ud) in all xenograft HSA tumors was detected in the same location as those original tumors. IHC; bars: 25 μm 
(A--D) and 50 μm (E--P).BMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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sponds to human VEGF-A165, is the dominant molecular
species. Canine VEGF-A164  contains all the necessary
information for the normal growth, remodeling, and pat-
terning of blood vessels [32]. Some reports investigate the
expression of VEGF-A variants in various human neo-
plasms [33-39]. The increased expression of human
VEGF-A165 and VEGF-A189 in osteosarcoma [33], renal cell
carcinoma [34], non-small-cell lung cancer [35-37], and
colon cancer [38] correlates with neovascularization,
tumor progression, and poor prognosis. In human angi-
osarcoma, the expression of VEGF-A mRNA has been
demonstrated, but the expression of VEGF-A variants has
not been investigated [40]. VEGF-A120 and VEGF-A164 have
been detected as major bands in canine HSA, while VEGF-
A144 and VEGF-A188 have been detected as minor bands;
however, spontaneous HSA contains contaminating
inflammatory cells that express VEGF-A mRNA [10]. In
the present study, primers for VEGF-A were expected to
produce 3 splicing variants, namely, VEGF-A164, VEGF-
A182, and VEGF-A188. VEGF-A164 and VEGF-A188 but not
VEGF-A182 were detected in all xenograft tumors and nor-
mal canine spleens. VEGF-A164 has been demonstrated to
have a higher expression as compared to the expression of
VEGF-A182  and VEGF-A188  in both spontaneous and
xenograft HSA tumors.
The expression of bFGF mRNA was different among the
xenografts. In 3 of the xenografts--Si, Ud, and Sy--the
expression levels of bFGF mRNA were found, by RT-PCR,
to be higher than those of other xenografts. The intensity
of specific bands for bFGF was similar to those of normal
canine spleen samples, which were used as a positive con-
trol; however, spleens contain various cells--including
leukocytes, ECs, and other stromal cells--and thus the
actual expression of bFGF in splenic ECs might be low.
Therefore, the expression levels of bFGF mRNA in Si, Ud,
and Sy might be high and must be measured quantita-
tively. bFGF is one of the most effective angiogenic growth
factors; therefore, it might play a role in malignant
endothelial growth in HSA.
In recent studies, it has been demonstrated that several
homeobox genes regulate the behavior of ECs during ang-
iogenesis and it is suggested that the homeobox proteins
of HoxA9, HoxD3, and Pbx1 are involved in the malig-
nancy of canine HSA [13,17,27]. HoxA9, HoxB3, HoxB7,
and HoxD3 proteins regulate the expression of down-
stream genes involved in angiogenesis; Pbx1 and Meis1
assist in the functioning of Hox protein, as cofactors
[16,41]. In the present study, immunostaining of
xenograft HSA tumors was positive for HoxA9, HoxB3,
HoxB7, HoxD3, Pbx1, and Meis1, which is similar to the
proteins detected by immunostaining of the original
tumors. The expression of HoxA9, HoxB3, HoxB7,
HoxD3, Pbx1, and Meis1 mRNA was also detected in all
xenograft tumors. HoxA9 mediates EC migration and pro-
liferation during angiogenesis by regulating the expres-
sion of EphB4, a member of the Eph receptor tyrosine
kinase family [13,42]. HoxA9 binds the EphB4 promoter
and induces the transcription of the EphB4 mRNA direc-
tory [13]. Therefore, the expression of EphB4 mRNA in all
xenograft tumors suggests that HoxA9 may induce the
expression of EphB4 in HSA. Moreover, HoxA9 has been
found to be a key regulator that induces acute myeloid
leukemia in mice [43]. Although coactivation of HoxA9
and Meis1 in mouse bone marrow cells has reportedly
induced acute myeloid leukemia rapidly, this phenome-
non was not observed in terms of an individual overex-
pression of each of the homeobox genes [41]. The
function of HoxA9 in HSA may have been enhanced by
the presence of Meis1.
HoxD3 both induces an angiogenic phenotype and
enhances the expression of both integrin αvβ3 and uroki-
nase-type plasminogen activator--the latter of which, in
turn, facilitates EC migration and adhesion during bFGF-
induced angiogenesis [17,44]. In human hemangioma,
expression levels of HoxD3 mRNA in the proliferation
phase are higher than those in the involution phase [45].
Pbx1 is known to be necessary for angiogenesis mediated
by HoxD3 [16]; therefore, one of the functions of HoxD3
is to induce ECs so that they are in an active phase--prolif-
erative and migratory--and it is suggested that HoxD3 is
involved in the tumorigenesis of canine HSA. Moreover,
HoxB3 promotes capillary morphogenesis during angio-
genesis, and HoxB7 directly upregulates the expression of
bFGF in human melanoma cells; the activation of bFGF
induces EC proliferation in vitro [14,46]. Finally, in 2
recent studies, it was demonstrated that Pbx1 functions as
a cofactor with HoxB3 and HoxB7 [47,48]. The result--
that HoxB7 and bFGF are expressed in HSA--may suggest
that HoxB7 induces the proliferation of tumor cells medi-
ated by bFGF.
The cytoplasmic localization of HoxA9, HoxB3, HoxD3,
Pbx1, and Meis1 proteins in original tumors was main-
tained in all xenograft HSA tumors. Previous studies have
shown the cytoplasmic localization of homeobox pro-
teins, suggesting modifications in their localization dur-
ing tumorigenesis [49-51]. The localization of homeobox
proteins might be involved in tumorigenesis in HSA.
Although xenograft models that demonstrate the expres-
sion of homeobox genes have been reported in human
small-cell lung cancers, there is no model available to ana-
lyze homeobox expression in HSA [52]. Recent studies
have indicated the possibility of a novel tumor therapy
that involves regulating aberrant expressions of home-
obox genes [53-55]; Plowright et al., for example, suggest
that the interaction between Hox and Pbx proteins is a
potential therapeutic target [56]. Therefore, the presentBMC Cancer 2009, 9:363 http://www.biomedcentral.com/1471-2407/9/363
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xenograft HSA models may be useful in evaluating a novel
molecularly targeted therapy involving homeobox pro-
tein.
In this study, no metastatic lesion was observed in any of
the xenograft tumors. Although there might not have been
sufficient time for the tumor to metastasize, the occur-
rence of metastasis depends on the mouse strains in the
xenograft tumors and tumor cell lines [57-59]. Therefore,
the metastasis model of xenografted canine HSAs may be
established by the transplanting the present xenograft
tumors into SCID or NOD-SCID mice. In general, ortho-
topic transplanted tumors have a greater tendency than
heterotopic transplanted tumors to metastasize to any
organ [60-62]. Therefore, orthotopic canine HSA trans-
plantation may lead to the development of metastatic
lesions in nude mice. It may be possible that the xenograft
tumors lost the expression of the factors required to
develop metastasis. Alternatively, metastasis-promoting
factors produced by xenograft canine tumors might not
react with mice. However, the relationship between
metastasis and the factors could not be elucidated in this
study.
Since the chemotherapy and radiotherapy was not carried
out in this study, the effects of these therapies for the
xenografted models are unclear. In medicine, surgical
resection and radiotherapy for HSA has been reported to
result in long-term survival in many cases [3,4]. On the
other hand, no standard chemotherapy for HSA has been
established; nevertheless, several approaches in chemo-
therapy have been attempted, such as liposomal doxoru-
bicin, interleukin-2, and interferon-α [63-65]. In recent
years, anti-angiogenic therapy has attracted considerable
attention as a possible therapy for HSA [66-68]. Given the
inferred mechanism of proliferation via VEGF-A or bFGF
in HSA, anti-angiogenic therapy would be the logical
strategy for the treatment of HSA [9,10]. Therefore, it is
hoped that the xenografted models, which are HSA
tumors producing VEGF-A, bFGF, and their receptors, will
be useful to evaluate the efficacy of the novel drug that
inhibits VEGF- or bFGF-mediated neoplastic proliferation
in HSA.
Conclusion
In the present study, 6 murine xenograft canine HSA
tumors were established. All xenograft tumors expressed
CD31, vWF, VEGF-A, bFGF, and their receptors; thus,
these tissues maintained endothelial characteristics, espe-
cially active ECs. Moreover, angiogenic homeobox genes
were expressed in the xenograft tissues. Together, these
xenograft canine HSA tumors constitute the first model to
demonstrate the expression of homeobox genes in HSA
and canine tumors. Since the tumors from the frozen
xenografts replicated the characteristics of original
tumors, the models are capable of reproducing
xenografted HSA tumors at any time. They may contribute
to elucidating the mechanism of HSA proliferation and
aid in the development of novel HSA therapy for dogs and
humans alike.
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